Navigation Links
New approach of resistant tuberculosis
Date:8/10/2012

only one percent had access to treatment. In 1991, a tuberculosis bug in New York was found to be resistant to 11 antibiotics. Cases have been reported where each and every antibiotic was useless. So far, these 'omniresistant' bacilli each time perished with their host before they could spread. So far, that is.

In 2012 on average 1 in 30 of new TB cases worldwide was multiresistant, with peaks of 1 in 3. With patients relapsing after a first cure, on average 1 in 5 was multiresistant, with peaks up to 65%. The highest numbers were all registered in the former Soviet Union. Without active measures the numbers will only rise.

If we want to prevent an epidemic of difficult to treat tuberculosis, then resistant cases, which do not react to the normal treatment, need to be recognized as early as possible, and immediately treated with second-line antibiotics that still work. But the laboratory tests to identify resistant TB bugs are cumbersome the WHO estimates that in 2009 only 11% of multiresistant cases were discovered.

Checking smears under the microscope still is the recommended technique for TB screening, but it cannot differentiate between living and dead bacilli. So you do not know if you are looking at the cadavers of a successful treatment, or at resistant survivors. Only if the numbers after a long wait still don't fall, you know you are dealing with a resistant strain. But all that time the patient has remained contagious.

With high-tech PCR technology one can immediately ascertain if the bacillus is from a resistant strain, but in practice and certainly in resource-limited countries this is unfeasible. It also is impossible to cultivate every sample and then bombard it with every possible antibiotic to survey which ones still work for that individual patient.

Armand Van Deun and colleagues therefore gave a new application to a forgotten technique: vital staining with fluorescein diacetate (FDA). It only stains living TB bacilli, so
'/>"/>

Contact: prof Bouke De Jong
bdejong@itg.be
32-324-76590
Institute of Tropical Medicine Antwerp
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. New line of approach for combination therapy against melanoma
2. Grassroots approach to conservation developed
3. Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy
4. Scientists urge new approaches to plant research
5. Computing advances vital to sustainability efforts; new report recommends problem-focused, iterative approach to research
6. Bugs have key role in farming approach to storing CO2 emissions
7. Potential new approach to regenerating skeletal muscle tissue
8. Powerful new approach to attack flu virus
9. New approach to spell checking gene sequences
10. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
11. Manatee hearing good enough to sense approaching motorboats
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New approach of resistant tuberculosis
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... factor for stroke, and its occurrence is closely related ... animals have shown that scavenger receptor class B type ... of scavenger receptor class B type I gene polymorphisms ... the exon 8 C1050T polymorphism, and these polymorphic loci ...
... During the last decade, our understanding of ... novel hypothalamic Arg-Phe-amide- related peptides, kisspeptin and ... the reproductive axis. Kisspeptins are currently recognized ... hypothalamus-pituitary-gonadal axis. Kisspeptin and its receptor, G ...
... The Bert L. and N. Kuggie Vallee Foundation announces, ... The 2013 winners are: Dr. Kirsty L. ... Molecular Biology at the Karolinska Institutet (Stockholm, Sweden) who ... fat cells. Dr. David Tobin, Assistant Professor of ...
Cached Biology News:
(Date:7/1/2015)... 1, 2015  UCB, a multinational biopharmaceutical company, ... leader in designing, transforming, and running intelligent business ... recognition of their close collaboration in driving transformation ... business services (GBS) finance organization. The ... that work together effectively to embrace the innovative ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix Corp. ... common shares of Resverlogix have approved the resolutions ... Capital Limited of 5,600,000 units at a price ... each unit being comprised of one common share ... proceeds of approximately CAD$15 million; and (ii) the ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... on developing therapeutics that address unmet medical needs ... George Elston will present at the Cantor ... July 8, 2015Time: , 4:45 PM EDTLocation: , ... & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest ... selectivity to achieve faster flow rates in comparison to nylon or polyethersulfone (PES). ... space to allow easy liquid flow while trapping particulates as small as 0.2 ...
Breaking Biology Technology:UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... 22, 2011 NeurogesX, Inc. (Nasdaq: NGSX ... management therapies, today announced that on July 21, 2011 ... with a private placement to a group of institutional ... expected to receive approximately $20 million in gross proceeds ...
... a significant threat to humans, as emphasized by the recent ... published on July 21st by the Cell Press journal ... of similar and divergent strategies that different toxins use to ... toxic protein derived from the castor bean plant that has ...
... ViroPharma Incorporated,s (Nasdaq: VPHM ) second quarter ... Thursday, July 28, 2011 before the open of the U.S. ... call and live audio webcast at 9:00 a.m. Eastern Time ... will discuss the 2011 second quarter financial results and other ...
Cached Biology Technology:NeurogesX, Inc. Announces $20 Million Private Placement 2NeurogesX, Inc. Announces $20 Million Private Placement 3NeurogesX, Inc. Announces $20 Million Private Placement 4Targeting toxin trafficking 2ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011 2
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
... Purpose -- The Varian 1200 ... highest level of flexibility and ... affordable, easy-to-use system. The complete ... guarantees success with today's applications ...
Biology Products: